Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 136 results

Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox

Japan27-05-2022Takanori Abe

Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.

Neurim, Flynn discover that time is not on their side

UK26-05-2022Lydia Birch

The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.

South Africa: homeopathy case clarifies ‘medicine’ defiinition

South Africa23-05-2022Kareema Shaik and Jenny Pienaar

South Africa’s Supreme Court has declared regulations on complementary medicines invalid, explain Kareema Shaik and Jenny Pienaar of Adams & Adams.

When alliances fail, is arbitration the answer?

24-02-2022

The global pandemic has increased collaboration and a new wave of disputes is likely. Arbitration is well placed to help, argue Kate Davies McGill, Gaela Gehring Flores and Paul Keller of Allen & Overy

NHS v Servier: unlawful means tort claim fails, but the long-running saga continues

UK17-08-2021Beatriz San Martin and Shishu Chen

The latest episode in the long-running dispute between the NHS and French pharmaceutical company Servier has been marked by a UK Supreme Court judgment of July 2, 2021 on Servier’s application to strike out the NHS’s unlawful means tort claim.

A new drug pricing system reform proposal in Japan

Japan17-08-2021Takanori Abe

A Japanese think tank is recommending an overhaul of Japan’s drug pricing system. Takanori Abe of Abe and Partners reports.

UK experimental use exemptions: Part 3—the expanded exemption

UK05-08-2021Sophie Topham

In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.

UK experimental use exemptions: Part 2—the Bolar exemption

UK22-07-2021Sophie Topham

In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.

UK experimental use exemptions: part 1—the original

15-07-2021Sophie Topham

In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement

The curious case of Wuhan’s Institute of Virology and remdesivir

China20-04-2021Thomas Moga

Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.

Showing 1 to 10 of 136 results

LSIPR